stockrow
Friday 6 November 2026
Export PBYI’s income statement to Excel — free account
Puma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024.
- Revenue
- +7.75%
- EPS
- +33.3%
- Free cash flow
- −88.5%
- Total debt
- −79.8%
Quarter to June 2026, against a year earlier
8.27
1.50
−15.35%
Follow PBYI
Alert me
Puma Biotechnology, Inc. (PBYI) P/E ratio
As of 6 November 2026, Puma Biotechnology, Inc. (PBYI) trades at a P/E ratio of 15.3×. Over the past ten years it has ranged from 0.0× (September 2023) to 2,295× (January 2023); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 9.4× | 88.89% |
| FY2024 | 5.0× | (49.23%) |
| FY2023 | 9.8× | (99.50%) |
| FY2022 | 1,967× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 15.0× | 17.52% |
| Mar 2026 | 12.8× | 35.32% |
| Dec 2025 | 9.4× | 33.40% |
| Sep 2025 | 7.1× | 102.29% |
| 32 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2,295×
Ten-year median
0.0×
Current reading's percentile
64
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| NGNE Neurogene Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| OVID Ovid Therapeutics compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. | 15.3× |
| YDES YD Bio Limited compare | — |
| SLBT SL SCIENCE HLDG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)